Nothing Found
Sorry, no posts matched your criteria
Center for Virology and Vaccine Research
3 Blackfan Circle
Boston, MA 02115 – USA
T 617.667.7000
F 617.735.4566
E CVVRcontact@bidmc.harvard.edu
CVVR Clinical Trials Unit
T 617.735.4610
E CVVRtrials@bidmc.harvard.edu
[DISPLAY_ULTIMATE_SOCIAL_ICONS]
Dr. Dan Barouch featured in Boston Magazine
/in NewsAs director of Beth Israel Deaconess’s Center for Virology and Vaccine Research, Barouch is behind a new vaccine that could stop the disease [HIV] in its tracks. [Boston Magazine article]
Dr. Dan Barouch Honored by the Massachusetts Society for Medical Research as Investigator of the Year
/in NewsWBUR Interview: HIV Prevention Could Need Cocktail Of Antibodies
/in NewsIt takes a cocktail of drugs to treat HIV. It could take a cocktail of antibodies to prevent HIV as well, suggests a study in Science Translational Medicine by Boston-based researchers […]
By Ganging Up, HIV Antibodies May Defeat the Virus
/in NewsExperimental Study Says Zika May Be Able to Treat Brain Cancer
/in News‘Mosaic’ HIV Vaccine Looks Good In Early Trial, Boston Researcher Tells AIDS Conference
/in NewsBy Carey Goldberg WBUR At a major international AIDS conference in Paris this week, researchers presented findings on a new HIV vaccine that look promising enough to launch a big clinical […]
More evidence treatment zeroes HIV transmission during sex while the world awaits a vaccine
/in NewsA new study found zero transmission of HIV between more than 370 homosexual couples. Preventing new infections while a vaccine is developed is key to controlling the epidemic.
There’s a promising new HIV vaccine candidate in the pipeline
/in NewsThe “mosaic vaccine” tackles the virus’s incredible genetic diversity.
Experimental HIV vaccine regimen is well-tolerated, elicits immune responses
/in NewsResults from early-stage NIH-funded trial support further development of candidate vaccines.
Investigational Preventative HIV Vaccine Well-Tolerated, Elicited Antibody Responses in Early Clinical Trials
/in NewsMosaic-based vaccine includes characteristics from several common strains of HIV.
In the APPROACH multi-site, randomized and controlled study of 393 healthy people in five countries, investigational vaccines were well-tolerated and elicited antibody responses in 100 percent of volunteers.